Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117 (1):143-50.

Article  PubMed  Google Scholar 

Tallini G, Tuttle RM, Ghossein RA. The History of the Follicular Variant of Papillary Thyroid Carcinoma. The Journal of clinical endocrinology and metabolism. 2017;102 (1):15-22.

Article  PubMed  Google Scholar 

Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nature reviews Molecular cell biology. 2008;9(7):517-31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood KW, Sarnecki C, Roberts TM, Blenis J. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell. 1992;68(6):1041-50.

Article  CAS  PubMed  Google Scholar 

Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370(6490):527-32.

Article  CAS  PubMed  Google Scholar 

McGrath JP, Capon DJ, Goeddel DV, Levinson AD. Comparative biochemical properties of normal and activated human RAS p21 protein. Nature. 1984;310(5979):644-9.

Article  CAS  PubMed  Google Scholar 

Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific Pattern of ras Oncogene Mutations in Follicular Thyroid Tumors. The Journal of Clinical Endocrinology & Metabolism. 2003;88(6):2745-52.

Article  CAS  Google Scholar 

Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, et al. Activated <em>ras</em> Oncogenes in Human Thyroid Cancers. Cancer Research. 1988;48(16):4459-63.

CAS  PubMed  Google Scholar 

Lemoine N, Mayall E, Wyllie F, Williams ED, Goyns M, Stringer B, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989;4(2):159-64.

CAS  PubMed  Google Scholar 

Gire V, Wynford-Thomas D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene. 2000;19:737.

Article  CAS  PubMed  Google Scholar 

Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009;69(8):3689-94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernandez-Prera JC, Valderrabano P, Creed JH, de la Iglesia JV, Slebos RJC, Centeno BA, et al. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021;31(1):36-49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suarez H, Du Villard J, Caillou Ba, Schlumberger M, Tubiana M, Parmentier C, et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene. 1988;2(4):403.

Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50(4):529-35.

Article  CAS  PubMed  Google Scholar 

Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. The Journal of clinical endocrinology and metabolism. 2013;98(5):E914-22.

Article  PubMed  PubMed Central  Google Scholar 

Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23(9):1191-200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JY, Kim WY, Hwang TS, Lee SS, Kim H, Han HS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013;24(2):69-76.

Article  CAS  PubMed  Google Scholar 

Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676-90.

Article  Google Scholar 

Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130(5):736-44.

Article  PubMed  Google Scholar 

Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28(10):1336-40.

Article  PubMed  Google Scholar 

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association. 2016;26(1):1-133.

Article  PubMed  Google Scholar 

Cibas ES, Ali SZ. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132(5):658-65.

Article  PubMed  Google Scholar 

Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-6.

Article  PubMed  Google Scholar 

Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta cytologica. 2012;56(4):333-9.

Article  PubMed  Google Scholar 

Roth MY, Witt RL, Steward DL. Molecular testing for thyroid nodules: Review and current state. Cancer. 2018;124(5):888-98.

Article  PubMed  Google Scholar 

Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocrine-related cancer. 2017;24(3):127-36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan H, Toraldo G, Cerda S, Godley FA, Rao SR, McAneny D, et al. Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort. Thyroid. 2020;30(4):536-47.

Article  CAS  PubMed  Google Scholar 

Valderrabano P, Khazai L, Thompson ZJ, Leon ME, Otto KJ, Hallanger-Johnson JE, et al. Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck. 2018;40(8):1812-23.

Article  PubMed  PubMed Central  Google Scholar 

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015;13:184-.

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019;5(2):204-12.

Article  PubMed  Google Scholar 

Marcadis AR, Valderrabano P, Ho AS, Tepe J, Swartzwelder CE, Byrd S, et al. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. Surgery. 2019;165(1):17-24.

Article  PubMed  Google Scholar 

An JH, Song KH, Kim SK, Park KS, Yoo YB, Yang JH, et al. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2015;82(5):760-6.

Article  CAS  PubMed  Google Scholar 

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015;13:184.

Article  PubMed  PubMed Central  Google Scholar 

Nabhan F, Porter K, Lupo MA, Randolph GW, Patel KN, Kloos RT. Heterogenei